Eisai CoESAIY +0.34%66 EV-to-FCF is 48.50 as of Jun. 25, 2026, which is 407% above its 10-year median of 9.56. GuruFocus rates ESAIY with a GF Score™ of 66/100 and a GF Value™ of $9.14 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 562 Drug Manufacturers companies, Eisai Co ranks worse than 76.16% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Eisai Co's Enterprise Value is $6,538 Mil.
Eisai Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $135 Mil. Therefore, Eisai Co's EV-to-FCF for today is 48.50.
The historical rank and industry rank for Eisai Co's EV-to-FCF or its related term are showing as below:
ESAIY'
s EV-to-FCF Range Over the Past 10 Years
Min: -290.87 Med: 9.56 Max: 756.23
Current: 48.5
During the past 13 years, the highest EV-to-FCF of Eisai Co was 756.23. The lowest was -290.87. And the median was 9.56.
ESAIY's EV-to-FCF is ranked worse than 76.16% of 562
companies
in the Drug Manufacturers industry
Industry Median: 20.11
vs ESAIY: 48.50
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Eisai Co's share price for today is $5.98.
Eisai Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.230.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Eisai Co EV-to-FCF Related Terms
Eisai Co EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Eisai Co's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Eisai Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eisai Co EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Eisai Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Eisai Co's EV-to-FCF falls into.
Eisai Co's current Enterprise Value is $6,538 Mil.
Eisai Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $135 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eisai Co (ESAIY) has a EV-to-FCF of 48.50 as of Jun. 25, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Eisai Co and its competitors. This is 407% above median its historical median of 9.56. According to the industry distribution chart, Eisai Co ranks #428 out of 562 companies in the Drug Manufacturers industry, placing it in the top 76.2%.
Is Eisai Co's EV-to-FCF too high?
Eisai Co's current EV-to-FCF of 48.50 is 407% above median its 10-year median of 9.56. The Drug Manufacturers industry median EV-to-FCF is 20.11. Eisai Co's value of 48.50 is 141.2% above this industry median. Based on the distribution chart, Eisai Co ranks #428 out of 562 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Eisai Co has a GF Score™ of 66/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eisai Co's EV-to-FCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Eisai Co ranks #428 out of 562 companies for EV-to-FCF. This places Eisai Co in the lower half of its industry. The industry median EV-to-FCF is 20.11. Eisai Co's value of 48.50 is 141.2% above this benchmark. While the company's 10-year median is 9.56 vs. the industry median of 20.11, Eisai Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.11, based on 562 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eisai Co's current EV-to-FCF of 48.50 is 141.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Eisai Co and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eisai Co's current EV-to-FCF is 48.50, which is 407% above median its own 10-year median of 9.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eisai Co stock overvalued right now?
Based on GuruFocus' analysis, Eisai Co (ESAIY) is currently considered Significantly Undervalued. The stock's GF Value™ is $9.14, compared to a current price of $5.98 — trading 34.6% below its estimated fair value. The current EV-to-FCF is 48.50, which is 407% above median its 10-year median of 9.56 and 141.2% above the Drug Manufacturers industry median of 20.11. Eisai Co's overall GF Score™ is 66/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Eisai Co (ESAIY), the current EV-to-FCF is 48.50 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eisai Co (ESAIY) Overvalued in 2026?
Based on GuruFocus' analysis, Eisai Co stock appears to be undervalued.
The current stock price of $5.98 is trading 34.6% below its estimated GF Value™ of $9.14.
GuruFocus considers Eisai Co to be Significantly Undervalued.
Key valuation signals for ESAIY:
EV-to-FCF: 48.50 (407% above median its 10-year median of 9.56)
GF Value™: $9.14 vs. price of $5.98 (34.6% below fair value)
Industry Position: 141.2% above the Drug Manufacturers median (#428 of 562)
No single metric tells the full story. See the ESAIY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eisai Co Ltd is a specialty and generic drug manufacturing company. The company's business consists of research and development, manufacturing, sales, import, and export of pharmaceuticals. The pharmaceutical business is categorized by region, including East Asia & Global South; Europe, Middle East, Africa, Russia, Oceania (EMEA); Americas; China; and Japan. The company also reports a consumer healthcare business for Japan. The vast majority of the company's revenue is derived from its American pharmaceutical business, followed by its Japanese pharmaceuticals segment. The company utilizes licensing strategies in order to expand its research, development, manufacturing, and marketing capabilities.
66GF Score
Get the complete analysis for ESAIY
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ESAIY has been successfully added to your 
